{"id":"atr","name":"ATR","symbol":"ATR","route":"/targets/atr/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:882","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175054","uniprot":"https://www.uniprot.org/uniprotkb/Q13535/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q13535","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5024","open-targets":"https://platform.opentargets.org/target/ENSG00000175054","civic":"https://civicdb.org/genes/545/summary","oncokb":"https://www.oncokb.org/gene/ATR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=ATR","depmap":"https://depmap.org/portal/gene/ATR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000175054-ATR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/545","omim":"https://www.omim.org/entry/601215"}],"products":[{"id":"ceralasertib","name":"Ceralasertib","status":"phase-3","modality":"small molecule","route":"/drugs/ceralasertib/"}],"trials":[{"id":"nct05450692","name":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","nct":"NCT05450692","phase":"3","status":"active"},{"id":"nct06732401","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","nct":"NCT06732401","phase":"3","status":"active"},{"id":"nct05061134","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","nct":"NCT05061134","phase":"2","status":"active"},{"id":"nct03334617","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","nct":"NCT03334617","phase":"2","status":"active"},{"id":"nct03330847","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","nct":"NCT03330847","phase":"2","status":"active"},{"id":"nct05941897","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","nct":"NCT05941897","phase":"2","status":"active"},{"id":"phoenix","name":"PHOENIX DDR/Anti-PD-L1","nct":"NCT03740893","phase":"2","status":"recruiting"},{"id":"nct05582538","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","nct":"NCT05582538","phase":"2","status":"recruiting"}],"pathways":["ddr","replication-stress","homologous-recombination-repair","p53-cell-cycle","synthetic-lethality-map","telomere-maintenance","p53-mdm2-axis"],"companies":["aprea-therapeutics","artios-pharma","astrazeneca","callio-therapeutics","repare-therapeutics"],"keyPapers":["paper-wardell-biliary-drivers-germline-j-hepatol-2018","paper-bao-glioma-stem-cells-radioresistance-nature-2006"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"top1-adc","mechanism":"SLFN11 loss","category":"payload"},{"class":"parp-inhibitor","mechanism":"Restoration of HR via 53BP1/Shieldin loss","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}